Virginia Oncology Associates

Summary

Virginia Oncology Associates is a medical facility located in Norfolk, Virginia. This center is recognized for care of Breast Cancer, Lung Cancer, Prostate Cancer, Cancer, Pancreatic Cancer and other specialties. Virginia Oncology Associates is involved with conducting 228 clinical trials across 190 conditions. There are 9 research doctors associated with this hospital, such as Michael A. Danso, Michael McCollum, Celeste A Bremer, and Paul Conkling, MD.

Top PIs

Clinical Trials running at Virginia Oncology Associates

Breast Cancer

Multiple Myeloma

Non-Hodgkin's Lymphoma

Prostate Cancer

Lung Cancer

B-Cell Lymphoma

Thrombocytopenic Purpura

Relapse

Melanoma

Non-Small Cell Lung Cancer

Ribociclib + Hormone Therapy

for Breast Cancer

The purpose of this open-label, multicenter, phase IIIb, single-arm study is to characterize the efficacy and safety of the combination of ribociclib and standard adjuvant endocrine therapy (ET) on invasive breast cancer-free survival (iBCFS), in a close to clinical practice patient population with HR-positive (HR+), HER2-negative (HER2-), Anatomic Stage Group III, IIB, and a subset of Stage IIA Early Breast Cancer (EBC).

Recruiting

2 awards

Phase 3

4 criteria

RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant

for Breast Cancer

This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutation following recurrence or progression on or after treatment with a CDK4/6 inhibitor.

Recruiting

2 awards

Phase 3

5 criteria

Elacestrant Combinations

for Breast Cancer

This is a multicenter, Phase 1b/2 trial in participants with estrogen receptor positive/human epidermal growth factor receptor 2 negative (ER+/HER2-) advanced/metastatic breast cancer. The phase 1b part of the trial will determine the recommended Phase 2 dose (RP2D) of elacestrant when administered in combination with alpelisib, everolimus, palbociclib, capivasertib, and ribociclib. The Phase 2 part of the trial will evaluate the efficacy and safety of the various combinations.

Recruiting

1 award

Phase 1 & 2